CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more


News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Scientists develop dry eye treatment using human antibodies

Study participants given eye drops containing human antibodies experienced a reduction in corneal damage

A new dry eye treatment incorporating human antibodies has successfully reduced corneal damage in a small trial.

Writing in The Ocular Surface, researchers report on the results of a study involving 27 patients with severe dry eye disease.

The participants were randomly assigned into two groups with one group given eye drops made from pooled antibodies and the other group given eye drops without antibodies.

Both groups administered the eye drops twice daily for eight weeks.

At the end of the trial period, there was a significant reduction in the signs and symptoms of dry eye disease in the group that received drops containing antibodies, with no difference in tolerability or adverse events.

Dr Sandeep Jain, from the University of Illinois’ College of Medicine, highlighted that there are currently only two approved drugs for the treatment of dry eye.

“They don’t work for everyone, especially those with severe dry eye disease, so having a new drug that can treat the disease by targeting a different mechanism, in this case, an autoimmunity, is very important,” he shared.

Image credit: Pixabay/roegger